2-(2,4-二氧代-1,2,3,4-四氢嘧啶-1-基)-N-(4-苯氧基苯基)乙酰胺作为一类新型巨细胞病毒复制抑制剂
2-(2,4-Dioxy-1,2,3,4-Tetrahydropyrimidin-1-yl)-N-(4-Phenoxyphenyl)-Acetamides as a Novel Class of Cytomegalovirus Replication Inhibitors.
作者信息
Babkov D A, Paramonova M P, Ozerov A A, Khandazhinskaya A L, Snoeck R, Andrei G, Novikov M S
机构信息
Volgograd State Medical University, Pavshikh Bortsov Sq., 1, Volgograd 400131, Russia.
Engelhardt Institute of Molecular Biology, Russian Academy of Science, Vavilov Str., 32, Moscow, 119991 , Russia.
出版信息
Acta Naturae. 2015 Oct-Dec;7(4):142-5.
Abstract
A series of novel uracil derivatives, bearing N-(4-phenoxyphenyl)acetamide moiety at N3 of a pyrimidine ring, has been synthesized. Their antiviral activity has been evaluated. It has been found that the novel compounds possess high inhibitory activity against replication of human cytomegalovirus (AD-169 and Davis strains) in HEL cell cultures. In addition, some of the derivatives proved to be inhibitory against varicella zoster virus.
摘要
合成了一系列新型尿嘧啶衍生物，这些衍生物在嘧啶环的N3位带有N-(4-苯氧基苯基)乙酰胺部分。对它们的抗病毒活性进行了评估。已发现这些新型化合物在人胚肺成纤维细胞（HEL）培养物中对人巨细胞病毒（AD-169和Davis株）的复制具有高抑制活性。此外，一些衍生物被证明对水痘带状疱疹病毒有抑制作用。
相似文献
1
2-(2,4-Dioxy-1,2,3,4-Tetrahydropyrimidin-1-yl)-N-(4-Phenoxyphenyl)-Acetamides as a Novel Class of Cytomegalovirus Replication Inhibitors.
Acta Naturae. 2015 Oct-Dec;7(4):142-5.
2
Toward the discovery of dual HCMV-VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides.
Bioorg Med Chem. 2015 Nov 1;23(21):7035-44. doi: 10.1016/j.bmc.2015.09.033. Epub 2015 Sep 21.
3
Synthesis and Antiviral Properties of 1-Substituted 3-[ω-(4-Oxoquinazolin-4(3H)-yl)alkyl]uracil Derivatives.
Acta Naturae. 2020 Jul-Sep;12(3):134-139. doi: 10.32607/actanaturae.10983.
4
'Synthesis, antiviral activity, molecular docking, and molecular dynamics studies of ethoxy phthalimide pyrazole derivatives against Cytomegalovirus and Varicella-Zoster virus: potential consequences and strategies for developing new antiviral treatments'.
J Biomol Struct Dyn. 2024;42(24):13903-13922. doi: 10.1080/07391102.2023.2279278. Epub 2023 Nov 15.
5
Synthesis, antiviral, cytotoxic and cytostatic evaluation of -(phosphonoalkyl)uracil derivatives.
Monatsh Chem. 2016;147(6):1081-1090. doi: 10.1007/s00706-016-1701-2. Epub 2016 Mar 1.
6
Synthesis of 1-[ω-(Bromophenoxy)alkyl]-3-Naphthalenylmethyl Uracil Derivatives and Their Analogues as Probable Inhibitors of Human Cytomegalovirus Replication.
Dokl Biochem Biophys. 2022 Dec;507(1):357-362. doi: 10.1134/S1607672922340099. Epub 2023 Feb 14.
7
Synthesis of 1-[ω-(Bromophenoxy)alkyl]-3-naphthalenylmethyl Derivatives of Uracil and Their Analogues As Probable Inhibitors of Human Cytomegalovirus Replication.
Dokl Biochem Biophys. 2023 Apr;509(1):41-46. doi: 10.1134/S1607672923700151. Epub 2023 Jun 20.
8
Synthesis and anti-HCMV activity of 1-[ω-(phenoxy)alkyl]uracil derivatives and analogues thereof.
Bioorg Med Chem. 2013 Jul 15;21(14):4151-7. doi: 10.1016/j.bmc.2013.05.009. Epub 2013 May 16.
9
Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
Eur J Med Chem. 2009 Sep;44(9):3591-5. doi: 10.1016/j.ejmech.2009.02.030. Epub 2009 Mar 9.
10
Synthesis and Ativiral Activity of 5-(Benzylthio)-4-carbamyl-1,2,3-triazoles Against Human Cytomegalovirus (CMV) and Varicella-zoster Virus (VZV).
Med Chem. 2017;13(5):453-464. doi: 10.2174/1573406413666170307165236.
本文引用的文献
1
A highly facile approach to the synthesis of novel 2-(3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-N-phenylacetamides.
Tetrahedron Lett. 2013 Feb 6;54(6):576-578. doi: 10.1016/j.tetlet.2012.11.090. Epub 2012 Nov 29.
2
Synthesis and anti-HCMV activity of 1-[ω-(phenoxy)alkyl]uracil derivatives and analogues thereof.
Bioorg Med Chem. 2013 Jul 15;21(14):4151-7. doi: 10.1016/j.bmc.2013.05.009. Epub 2013 May 16.
3
N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
Bioorg Med Chem. 2013 Mar 1;21(5):1150-8. doi: 10.1016/j.bmc.2012.12.027. Epub 2013 Jan 3.
4
Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
Transplantation. 2012 Jun 15;93(11):1075-85. doi: 10.1097/TP.0b013e31824810e6.
5
Antiviral treatment of cytomegalovirus infection.
Infect Disord Drug Targets. 2011 Oct;11(5):475-503. doi: 10.2174/187152611797636640.
6
Antiviral drug resistance of human cytomegalovirus.
Clin Microbiol Rev. 2010 Oct;23(4):689-712. doi: 10.1128/CMR.00009-10.
7
Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection.
Rev Med Virol. 2010 Jul;20(4):202-13. doi: 10.1002/rmv.655.
8
Gastrointestinal cytomegalovirus disease in the immunocompromised patient.
Curr Gastroenterol Rep. 2008 Aug;10(4):409-16. doi: 10.1007/s11894-008-0077-9.
9
New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection.
Rev Med Virol. 2007 Sep-Oct;17(5):355-63. doi: 10.1002/rmv.544.
10
Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.
Lancet Infect Dis. 2004 Dec;4(12):725-38. doi: 10.1016/S1473-3099(04)01202-2.
Zotero 插件